Inmaculada Castillo

Inmaculada Castillo

Auto-generated profile, based on publicly available information

Inmaculada Castillo

Fundación para el Estudio de las Hepatitis Virales, Madrid, Spain

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ICInmaculada Castillo
Inmaculada Castillo
MPMargarita Pardo
Margarita Pardo
JBJavier Bartolomé
Javier Bartolomé
NONuria Ortiz‐Movilla
Nuria Ortiz‐Movilla
ERElena Rodríguez‐Iñigo
Elena Rodríguez‐Iñigo
VCVicente Carreño
Vicente Carreño
BackgroundThere are patients in whom the etiology of long-standing abnormal results of liver-function tests is unknown (ALF-EU) after exclusion of al

10 September 2004 in Gut
Verified
Journal Article
Open access
PDF file
BVB J Veldt
B J Veldt
GSG Saracco
G Saracco
NBN Boyer
N Boyer
CCCalogero Cammà
Calogero Cammà
ABA Bellobuono
A Bellobuono
SSS W Schalm
S W Schalm
Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 biochemical responders (detectable virus but normal alanine aminotransferase levels) were followed up for 59 months. Fifteen sustained virological responders (5.2%) had cirrhosis before treatment and 112 (39%) had genotype 1. The late virological relapse rate after five years of follow up was 4.7% (95% confidence interval (CI) 2.0–7.4) among sustained virological responders; all late relapses occurred within four years after treatment. Among sustained virological responders, the rate of decompensation after five years of follow up was 1.0% (95% CI 0.0–2.3) and none developed hepatocellular carcinoma (HCC). Survival was comparable with the general population, matched for age and sex, the standard mortality ratio being 1.4 (95% CI 0.3–2.5). Clinical outcome of patients with cirrhosis was similar to other sustained virological responders. For biochemical responders, the rates of development of decompensation and HCC during long term follow up were 9.1% (95% CI 0.5–17.7) and 7.1% (95% CI 0–15.0), respectively. Conclusions: Five year survival of European sustained virological responders was similar to the overall population, matched for age and sex. No HCCs were detected during long term follow up.

14 April 2005 in Gut
Verified
Journal Article
Open access
PDF file
ICI Castillo
I Castillo
ERE Rodríguez-Iñigo
E Rodríguez-Iñigo
JBJ Bartolomé
J Bartolomé
SLS de Lucas
S de Lucas
NON Ortíz-Movilla
N Ortíz-Movilla
VCV Carreño
V Carreño
Background: Occult hepatitis C virus (HCV) infection is characterised by the presence of HCV-RNA in the liver in the absence of anti-HCV, and serum viral RNA. Up to 70% of these patients also have HCV-RNA in peripheral blood mononuclear cells (PBMC) but it is not known if HCV is replicating in these cells. Aim: We studied possible HCV replication in PBMC of 18 patients with an occult HCV infection who were selected on the basis of HCV-RNA positivity in PBMC. Methods: Detection of HCV-RNA positive and negative strands in PBMC was done by strand specific reverse transcriptase-polymerase chain reaction (RT-PCR) and by in situ hybridisation. Results: The presence of HCV-RNA positive strand in PBMC was confirmed in all patients by strand specific RT-PCR and by in situ hybridisation. Mean percentage of PBMC which had the HCV-RNA positive strand was 3.3% (95% confidence interval (CI) 2.1–4.4) The HCV-RNA negative strand was found in the PBMC of 11/18 (61%) patients by strand specific RT-PCR and confirmed by in situ hybridisation, and the percentage of PBMC harbouring the HCV-RNA negative strand was 3.1% (95% CI 0.8–5.5). There was a significant correlation (p = 0.001, r = 0.84) between the percentage of PBMC with the HCV-RNA positive strand and that of PBMC with the HCV-RNA negative strand. Conclusion: HCV replicates in the PBMC of patients with occult HCV infection and thus, although these patients do not have serum HCV-RNA, they could be potentially infectious.

15 November 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ICInmaculada Castillo
Inmaculada Castillo
ERElena Rodríguez-Iñigo
Elena Rodríguez-Iñigo
JLJuan Manuel López-Alcorocho
Juan Manuel López-Alcorocho
MPMargarita Pardo
Margarita Pardo
JBJavier Bartolomé
Javier Bartolomé
VCVicente Carreño
Vicente Carreño
Background. Positive-strand hepatitis C virus (HCV) RNA has been detected in the livers of patients who have achieved a sustained biochemical and vir

1 December 2008 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
GBGuillermina Barril
Guillermina Barril
ICInmaculada Castillo
Inmaculada Castillo
MAMaría Dolores Arenas
María Dolores Arenas
MEMario Espinosa
Mario Espinosa
JGJuan Garcia-Valdecasas
Juan Garcia-Valdecasas
VTVicente Carren[Combining Tilde]O
Vicente Carren[Combining Tilde]O
Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and anti-HCV antibodies has not been investigated in hemodialysis patients. In this study, real-time PCR and in situ hybridization was used to test for the presence of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of 109 hemodialysis patients with abnormal levels of liver enzymes. Occult HCV infection, determined by the presence of genomic HCV-RNA, was found in 45% of the patients; 53% of these patients had ongoing HCV replication, indicated by the presence of antigenomic HCV-RNA. Patients with occult HCV infection had spent a significantly longer time on hemodialysis and had significantly higher mean alanine aminotransferase levels during the 6 mo before study entry. Logistic regression analysis revealed that mortality was associated with age >60 yr (odds ratio 3.30; 95% confidence interval 1.05 to 10.33) and the presence of occult HCV infection (odds ratio 3.84; 95% confidence interval 1.29 to 11.43). In conclusion, the prevalence of occult HCV infection is high among hemodialysis patients with persistently abnormal values of liver enzymes of unknown cause. The clinical significance of occult HCV infection in these patients requires further study.

1 February 1991 in Hepatology
Verified
Journal Article
Closed access
PDF file
FSFederico Sáez-Royuela
Federico Sáez-Royuela
JPJuan Carlos Porres
Juan Carlos Porres
AMAlberto Moreno
Alberto Moreno
ICInmaculada Castillo
Inmaculada Castillo
GMGracia Martinez
Gracia Martinez
VCVicente Carreño
Vicente Carreño